IMI fosters antibiotics research amidst Bi...The Innovative Medicines Initiative 2 (IMI2) has launched a new Antimicrobial Resistance Accelerator Programme following on the heels of its outgoing NewDrugs4BadBugs programme. more ➔
Experts discuss process intensificationRoughly 150 life science professionals met at the 5th Biotech Days to discuss the latest progress in bioprocess intensification. more ➔
Managing complexity to bring drugs to clin...Integrating the disparate stages of drug development is the most time and cost-efficient way of turning a promising candidate compound into a pharmaceutical product. A CDMO that offers coordinated end-to-end … more ➔
The future of agrochemistryOne of the world’s largest and most controversial mergers in the past few years was sealed in early June. German pharma and chemistry company Bayer has taken over US competitor Monsanto, forming the … more ➔
Closing the gap in haemophilia therapyAbout 25% of the people who suffer from haemophilia A have no therapeutic options, because their immune system forms antibodies against clotting products that can stop bleeding. Researchers and companies … more ➔
A global CMO for medical mediaBiological Industries (BI) develops, manufactures, packs, and supplies cell culture products for academic research, diagnostic labs, hospitals, and the biotechnology and biopharmaceutical industries. … more ➔
Nanobots: Fiction becoming realityOnce confined to speculative and science fiction, miniature micro- or nanobots targeting pathogens or conditions directly have now become reality in research labs worldwide. But to enter clinical trials, … more ➔
Crowdfunding goes blockchainSpanish Capital Cell continues to be a pioneer in the health crowdfunding scene and launched a new self-funding fundraising round to create the first ICO marketplace for health via Blockchain. more ➔
Determined to reduce the risk of bleedsAnalysts say Roche’s bispecific antibody Hemlibra will rock the US$15bn haemophilia A market, given that it may circumvent therapy resistance that affects the 30% of patients who form antibodies against … more ➔
User-driven early certainty: EPO steps bac...It was too good to be true. Following harsh criticism from industry, the European Patent Office (EPO) drafted a widely applauded proposal to allow exemptions to its Early Certainty Initiative in Examination. … more ➔
